Winning Health(300253)2023-07-09 16:00Sales and Revenue - The total sales amount from the top five customers is ¥165,412,462.81, accounting for 5.35% of the annual total sales[1]. - The company's revenue for 2022 was CNY 3,092,864,688.21, representing a 12.46% increase from CNY 2,750,202,059.34 in 2021[76]. - Quarterly revenue for Q4 2022 reached CNY 1,221,899,498.11, contributing to the overall annual growth[77]. - The revenue from healthcare information technology business accounted for 81.75% of total revenue, with a year-on-year growth of 9.40%[108]. - The internet healthcare business revenue grew by 28.38%, accounting for 18.21% of total revenue[108]. - The revenue from software products was CNY 265.83 billion, representing a year-on-year increase of 9.9%[89]. - The revenue from information technology services was CNY 701.28 billion, with a year-on-year growth of 11.7%[89]. - The company achieved operating revenue of 3,092.86 million yuan, a year-on-year increase of 12.46%[108]. - The revenue from hardware sales was approximately ¥459.21 million, with a gross margin of 11.17%[120]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[177]. Expenses and Costs - Sales expenses increased by 28.10% year-on-year, totaling ¥495,871,530.24 in 2022[2]. - R&D expenses rose by 22.73% year-on-year, amounting to ¥313,773,819.41 in 2022[2]. - The company's main business costs for 2022 amounted to 1,234,582,227.79 yuan, representing 70.89% of total operating costs, compared to 1,079,886,962.74 yuan and 73.19% in 2021, reflecting a year-on-year increase of 14.33%[48]. - Software development labor costs were 306,785,778.95 yuan, accounting for 17.62% of operating costs, up from 15.15% in 2021, marking a 37.26% increase[48]. - Hardware material costs reached 407,902,261.69 yuan, which is 23.42% of operating costs, compared to 26.02% in the previous year, with a year-on-year increase of 6.24%[48]. - Technical service labor costs were 153,438,165.94 yuan, making up 8.81% of operating costs, slightly down from 9.13% in 2021, with a year-on-year increase of 13.88%[48]. - The gross margin for the healthcare information technology sector was reported at 51.17%, a decrease of 2.11% compared to the previous year[120]. - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[177]. Research and Development - The number of R&D personnel increased by 9.90% to 2,487 in 2022[7]. - R&D investment reached ¥625,518,769.72 in 2022, accounting for 20.22% of operating revenue[7]. - The proportion of capitalized R&D expenses to total R&D investment is 49.84% in 2022[7]. - The company is currently working on six major R&D projects aimed at enhancing product competitiveness[7]. - The company reported a total R&D capitalization amount of ¥278,299,228.09 for the development of next-generation smart medical products and cloud services, which are currently in progress[10]. - The company invested ¥625 million in R&D, accounting for 20.22% of total revenue, and obtained 47 new patents during the reporting period[114]. Cash Flow and Investments - Operating cash inflows for 2022 reached ¥3,456,104,778.63, representing a year-on-year increase of 15.51%[14]. - The net cash flow from operating activities decreased by 72.71% to ¥100,441,940.18, primarily due to increased cash payments to employees[14]. - The investment activities generated a net cash outflow of ¥349,790,906.68, reflecting a slight increase in outflows compared to the previous year[14]. - The company incurred an investment loss of ¥65,675,691.37, accounting for -170.41% of total profit, indicating significant challenges in investment performance[15]. - The total investment amount for the reporting period was ¥160,630,100, a decrease of 65.74% compared to ¥468,916,000 in the same period last year[29]. Profitability - In 2022, the company achieved a net profit attributable to shareholders of 108.44 million yuan, a decrease of 71.33% year-on-year[48]. - The net profit attributable to shareholders for 2022 was CNY 108,436,489.10, a decrease of 71.33% compared to CNY 378,174,115.45 in 2021[76]. - The basic earnings per share for 2022 was CNY 0.0507, a decline of 71.27% from CNY 0.1765 in 2021[76]. - The net profit attributable to shareholders of the listed company was approximately CNY 31.76 million, a decrease of 31.6% compared to the previous period[79]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 30.57 million, down 20.4% year-on-year[79]. Market and Industry Trends - The software and information technology service industry in China saw a revenue growth of 11.2% year-on-year, reaching CNY 1,081.26 billion in 2022[89]. - As of 2022, there are over 1,700 internet hospitals in China, with online medical user numbers exceeding 300 million, reflecting a significant increase in demand for online consultations and services[97]. - The "14th Five-Year" plan emphasizes the promotion of hospital information system cloud deployment, which is expected to enhance operational efficiency and data sharing capabilities[97]. - The integration of artificial intelligence in medical applications is being accelerated, with seven key scenarios identified for exploration, including intelligent diagnostic support and smart hospital management[93]. - The demand for data-driven systems and platforms in hospitals is increasing, as there is a need to unlock the value of accumulated data for clinical, research, and management purposes[97]. Strategic Initiatives - The company plans to focus on new product development and market expansion strategies in the upcoming year[68]. - The company is focusing on expanding its cloud services for healthcare institutions, including medical cloud and community cloud offerings[10]. - The company continues to invest in the WiNEX series products and the "Internet + Healthcare" innovation and market expansion, driven by technological innovation[48]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a target of 500 million RMB in potential acquisitions[177]. - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online sales[177].